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Abstract
Aim: To identify risk factors for a non-favourable long term outcome with respect to Health 
Related Quality of Life (HRQoL) and fatigue after treated Lyme Neuroborreliosis (LNB).
Methods: We followed 50 LNB patients, and assessed outcome by the self-report 
questionnaires Short Form-36 (SF-36) and Fatigue Severity Scale (FSS) 30 months after 
treatment. We analyzed associations between these outcomes and demographical, clinical and 
laboratory data by univariate analyses and linear regression. Clinical status was assessed by a 
composite score based on subjective complaints and objective findings.
Results: Pre-treatment symptom duration > 6 weeks (B=-10.2, P=0.002) and non-complete 
recovery at 12 months (B=-5.6, P=0.033) were associated with lower scores in the SF-36
domain Physical Component Summary (R2=0.59). Non-complete recovery at 4 months was
associated with lower scores in the SF-36 domain Mental Component Summary (B=-8.9, 
P=0.01 (R2= 0.37)). Pre-treatment symptom duration > 6 weeks (B=1.3, P= 0.028), high 
scores on the composite clinical score pre-treatment (B=0.1, P=0.019) and non-complete
recovery at 12 months (B=1.7, P=0.001) were associated with higher FSS scores (R2=0.70). 
No laboratory test results were associated with these outcomes.
Conclusions: Delayed treatment start, more symptoms and findings before and non-complete 
recovery at 4 and 12 months after treatment seem to predict a non-favourable outcome
regarding HRQoL and fatigue 30 months after treated LNB. Age, gender, educational level 
involvement of the central nervous system pre-treatment, coexisting diseases and 
cerebrospinal fluid findings before treatment and during follow-up, were not associated whit 
long term HRQoL and fatigue.
INTRODUCTION
Lyme Neuroborreliosis (LNB) is usually effectively treated with antibiotics (1), but persisting 
complaints occur (2-4). Objective neurological findings after treated LNB are usually mild, 
but symptoms such as musculoskeletal pain, fatigue, cognitive deficits and reduced Health 
Related Quality of Life (HRQoL) are commonly reported (5-12). If such symptoms persist for 
more than 6 months after a documented episode of Lyme disease treated with a generally
accepted antibiotic regime, the symptoms are of such a severity that they result in reduction in 
previous level of functions, and there are no other obvious explanations of the symptoms, the 
condition is proposed defined as Post-Lyme Disease Syndrome (PLDS) (13). Despite several 
theories such  as persisting infection, autoimmunity, disturbances in the hormone axis, 
anxiety, depression and permanent tissue damage, the underlying pathology of  PLDS is still 
unknown (14). Imaging of the brain does not show specific abnormalities (15,16) and 
persistent infection is unlikely as prolonged antibiotic treatment does not improve the 
outcome permanently and is not recommended (7,17-20).
It is important to increase our understanding of the remaining complaints after treated LNB, 
and one approach is to identify risk factors for a non-favorable outcome. It has been reported 
that fatigue, neurocognitive deficits, arthralgia and residual neurological findings are more 
common if the treatment is delayed (2,3,5,8,21), but to our knowledge predictors of HRQoL
has not been addressed in European LNB studies until now. 
The aim of our study was to identify possible clinical, demographical and laboratory factors
associated with reduced HRQoL and fatigue 30 months after antibiotic treatment in a cohort 
of LNB patients.
MATERIAL AND METHODS
Patients and variables
From 2004 to 2008 we included 102 consecutive adult patients diagnosed with LNB in a 
multicenter treatment trial in Southern Norway (22). Out of these, 64 patients were recruited 
from two of the nine participating hospitals, covering the high endemic region of the Agder 
Counties. Fifty-seven of the 64 patients were included in the period May 2004-December 
2007 and were all invited to participate in the current follow-up study. Fifty patients
consented and were included. Neither the patients from the treatment trail who were not 
recruited to this follow-up study, nor the seven patients who were invited, but not included, 
differed from the 50 included patients regarding treatment or severity of the disease before 
and 4 months after treatment. The patients were treated with doxycycline (n=26) or 
ceftriaxone (n=24), and were classified as having definite (n=34) or possible (n=16) LNB 
according to the European Foundation of Neurological Society diagnostic guidelines (23).
Mean pre–treatment symptom duration was 9.2 weeks (Standard Deviation (SD) =19), 10
patients had pre-treatment duration of symptoms > 6 weeks, four of them >6 months (104, 76, 
52 and 28 weeks, respectively).
Forty of the patients (80%) presented with partial or complete Bannwart syndrome (facial 
palsy (n=8), other cranial nerve affection (n=4), paresis arm/leg (n=8), radiculitis (n=20) with 
lymphocytic CSF pleocytosis). Other affections were plexopathy (n=1), findings indicating 
CNS involvement (myelitis (n=1), ataxia (n=2) or confusion (n=1)), and recent onset 
subjective symptoms (n=5) (headache, joint pain, myalgias, malaise, asthenia). All 
assessments took place in the Department of Neurology at Sørlandet Hospital. The 
participants filled in the questionnaires Short Form-36 (SF-36) and the Fatigue Severity Scale 
(FSS) 30 months (range 27-34) after treatment. We collected demographical, laboratory and 
clinical data pre-treatment and at 4, 12 and 30 months after treatment. The patients were asked 
about comorbidity and previous or current psychiatric problems. All patients underwent a 
lumbar puncture pre-treatment, 42 at 4 months, 33 at 12 months, and 29 at 30 months. We 
analyzed cell-count, protein level, anti-Borrelia antibodies and oligoclonal bands in the 
cerebrospinal fluids (CSF). CXCL-13 level was assessed in all patients pretreatment and 10 
patients at 30 months. Based on a previous study we chose a CXCL-13 cut-off concentration 
of > 0 ng/g total CSF protein (24). Clinical outcome/burden of complaints was assessed by a 
composite clinical score (range 0-64) based on subjective reported complaints and clinical 
neurological findings (Table 1).
Table 1 Composite clinical score Lyme Neuroborreliosis patients. Previously published (22)
Clinical outcome score is the sum of subjective and objective findings. Each item is scored 0 
= no, 1 = mild, 2 = severe (maximum total score 64). * Left and right sides scored separately.
Mean (SD) composite clinical scores pre-treatment, at 4 and 12 months were 8.3 (4.2), 2.7 
(3.3) and 1.4 (0.9), respectively. A clinical score of > 1 was regarded as non-complete 
recovery. We reviewed individual hospital records to confirm the patients past medical 
history.
Outcome was measured by HRQoL in terms of Physical Component Summary (PCS) and 
Mental Component Summary (MCS) (range 0-100) on the SF -36 questionnaire, and by 
fatigue in terms of scores on the FSS questionnaire (range 0-7) 30 months after treatment.
The mean PCS was 44 (SD=9), mean MCS was 49 (SD=11), and mean FSS score was 3.5 
(SD=2.4) in our cohort (previously published (9)). Five of the patients fulfilled the diagnostic 
criteria of PLDS (13). Anti-Tick Borne Encephalitis (TBE) virus antibodies in serum were 
tested in all patients, three were positive for IgG, and none for IgM. We did not test for 
Anaplasma antibodies, but none of the participants had a clinical picture or a blood count 
suggestive of Anaplasma infection.
Subjective complaints
(maximum score = 12)
Objective findings
(maximum score = 52)
Malaise
Fatigue
Pain
Memory problems
Concentration difficulties
Paresthesia
Facial palsy *
Reduced hearing*
Vision loss l/r
Reduced sensibility in face*
Paresis of eye muscles*
Other cranial neuropathies
Tremor
Ataxia
Nuchal rigidity
Confusion
Other CNS findings
Radiculopathy truncus *
Radiculopathy arm*
Radiculopathy leg*
Paresis arm*
Paresis leg*
Ethics
All participants gave written informed consent. The study was approved by the Regional 
Committee for Medical Research Ethics in Southern Norway, and by the Norwegian Data 
Inspectorate.
This trial is a follow-up study on the treatment trial registered with ClinicalTrials.gov number 
NCT00138801
Statistical analysis
The statistical software SPSS version 16 was used for all analyses. For analyses of association 
between the continuous endpoints PCS, MCS and FSS and possible risk factors we did 
univariate analyses using Pearson’s correlation for independent continuous variables and 
Student t-test for comparisons of means between groups. Education level was split into 3 
levels and analyzed with Analysis of Variance (ANOVA). To be able to do a simultaneous 
assessment of multiple potential risk factors, all variables with P-values of 0.150 or less in 
the univariate analyses were included stepwise in a multiple linear regression model, one 
model for each of the three outcomes, PCS, MCS, and FSS. Because of missing data the CSF 
variables were analyzed separately. The results are presented with B-coefficient and with 95% 
confidence intervals (CI). P-values <0.05 were considered as statistical significant. We also 
report the R2 (coefficient of determination) for each model. R2 indicates how much of the 
variance in the outcome that is explained by the model.
RESULTS
Results of the univariate analyses of possible predictors of outcome are summarized in Table 
2 and 3.
Table 2 Associations between categorical demographic, clinical and laboratory variables and 
Health Related Quality of Life and fatigue 30 months after treated Lyme Neuroborreliosis.
*The difference is between the group with 4-6 years education and the group with more than 7 years of 
education after primary school. SD= Standard Deviation, CI= Confidence Interval, PCS= Physical Composite 
Summary and MCS=Mental Component Summary of the Health Related Quality of Life questionnaire SF-36 
(Short Form 36) 0- 100 (no problems), FSS =Fatigue Severity Scale ( 0 (no problems) -7), BAB= Borrelia Anti 
Bodies, OCB= Oligo Clonal Bands, CNS= Central Nervous System, CSF= Cerebro Spinal Fluid. 
PCS MCS FSS 
Variable (n) Mean (SD) P-value Mean (SD) P-value Mean (SD) P-value
Gender 
Male (27)
Female (21)
45.2 (11.1)
44.2 (8.2)
0.738 50.9 (11.5)
48.6 (11.9)
0.501 3.5 (2.0)
3.5 (2.0)
0.950
Education: years after primary school*
0-3  (24)
4-6 (16)
>7  (10)
44.1 (7.9)
41.2 (12.1)
51.6 7.4)
0.030 48.7 (14.2)
52.3 (9.6)
49.0 (7.7)
0.646 3.7(2.0)
3.5 (2.4)
3.0 (1.3)
0.667
Comorbidity pre-treatment
Yes: (20)
No: (30)
39.9 (10.1)
47.9 (8.5)
0.005 48.5 (13.6)
50.8 (10.3)
0.576 4.4 (1.9)
2.9 (1.8)
0.009
Treatment
Ceftriaxone (26)
Doxycycline(24)
45.4 (10.9)
44.1 (9.0)
0,642 47.7 (12.6)
52.1 (10.3)
0.186 3.9 (1.9)
3.1 (2.1)
0.226
Diagnostic accuracy
Definite(34)
Possible (16)
45.5 (8.8)
43.3 (12.0)
0.471 49.0 (12.0)
51.8 (11.0)
0.426 3.4 (2.0)
3.7 (1.9)
0.627
Pre-treatment CNS manifestations
Yes: (4)
No: (46)
42.8 (4.8)
44.9 (10.2)
0.731 50.1 (18.3)
49.9 (11.4)
0.973 3.4 (2.5)
3.5 (2.0)
0.920
Pre-treatment duration > 6 weeks
Yes: (10)
No:(38)
34.6 (8.5)
47.4 (8.5)
<0.001 48.1 (13.2)
50.4 (11.3)
0.590 5.4 (1.9)
3.0 (1.7)
<0.001
Recovery 4 months
Yes: (18)
No:( 32)
49.9 (6.4)
41.9(10.4)
0.006 55.6 (4.7)
46.8 (13.1)
0.001 2.1 (1.9)
4.2 (1.2)
<0.001
Recovery 12 months
Yes:  (29)
No:( 21)
48.6 (9.1)
39.8 (8.7)
0.002 51.7 (8.3)
47.6 (14.9)
0.233 2.5 (1.6)
4.9 (1.6)
<0.001
Intrathecal BAB  production 30 months
Yes:(17)
No: (11)
44.1(10.1)
43.3 (11.8)
0.875 51.9 (9.1)
45.3 (16.5)
0.195 3.4 (2.1)
3.6 (2.1)
0.788
CSF OCBs pre-treatment 
Yes: (24)
No:(13)
45.9 (8.9)
43.9 (7.4)
0.498 52.4 (9.3)
46.4 (13.5)
0.127 3.3 (1.7)
3.5 (2.3)
0.725
CSF OCBs 30 months  
Yes: (12)
No:( 16)
44.1(9.4)
43.5 (11.8)
0.888 44.7 (10.7)
52.8 (14.1)
0.101 4.0 (2.1)
3.9 (2.1)
0.906
Table 3 Correlations of continuous demographic, clinical and laboratory variables with Health 
Related Quality of Life and fatigue 30 months after treated Lyme Neuroborreliosis
As previously reported (9) we found that 14 of the patients had neurological findings 30 
months after treatment: slight facial paresis (n=3), reduced hearing (n=1), reduced sense of 
feeling in the face (n=3), anisocoria (n=1), tremor (n=2), ataxia (n=2), nystagmus (n=2), 
radiculopathy (n=6) and slight arm/leg paresis (n=4) (ten had more than one finding). Twenty 
PCS MCS FSS
Variables* Mean 
(SD)
Pearson`s
Correlation 
Coefficient 
[95% CI]
P-
value
Pearson`s
Correlation 
Coefficient 
[95% CI]
P-
value 
Pearson`s
correlation 
Coefficient 
[95% CI]
P-value
Age in years 56 (13) -0.165 [-
0.429-
0.124]
0,262 0,029 [-
0.257-0.31]
0.847 0.148 [-
0.135-
0.409]
0.305
Clinical score 
pre -treatment 
8.3 (4.3) -0.251 [-
0.499-
0.035]
0.086 -0.243 [-
0.493-
0.044]
0.096 0.449 
[0.196-
0.646]
0.001
CSF cell count 
pre-treatment
(cells/mm3)
187
(255)
-0.079 [-
0.355-
0.209]
0.594 -0.088 [-
0.363-
0.201]
0.552 0.158 [-
0.125-
0.417]
0.273
CSF cell count 
4 months 
(cells/mm3)
7.8 
(11.4)
-0.031 [-
0.339-
0.283]
0.852 0.017 [-
0.296-
0.326]
0.981 0.046 [-
0.261-
0.345]
0.771
CSF cell count 
12 months 
(cells/mm3)
(n=29)
3.72 
(12.1)
0.011 [-
0.363-
0.382]
0.955 -0.333 [-
0.628-
0.045]
0.084 0.144 [-
0.234-
0.484]
0.458
CSF protein 
level pre-
treatment (g/l )
1.22 
(0,73)
0.088 [-
0.201-
0.363]
0.551 0.114 [-
0.175-
0.385]
0.441 -0.020 [-
0.296-
0.259]
0.891
CSF protein 
level  4 
months (g/l) 
(n=42)
0.61 
(0.24)
-0.017 [-
0.326-
0.296]
0.095 -0.086 [-
0.387-
0.231]
0.600 0.263 [-
0.044-
0.524]
0.093
CSF protein 
level 30 
months (g/l) 
(n=29)
0.51 
(0.20)
0.064 [-
0.316-
0.426]
0.747 -0.237 [-
0.56-0.149]
0.224 0.134  [-
0.244-
0.477]
0.488
CSF CXCL 13 
level pre-
treatment
(n=32)
5227
(11915)
-0.194 [-
0.513-
0.172]
0.296 -0.002[-
0.356-
0.352]
0.990 0.232 [-
0.126-
0.537]
0.202
patients had only subjective complaints, slight feeling of malaise (n=5), fatigue (n=15), pain
(n=7), paraesthesias (n=7), memory (n=13) and concentration problems (n=9).
Ten patients reported previous or current psychiatric problems, two of them used anti-
depressive medication at the time of follow-up because of a depressive disease. The other 
eight patients had minor psychiatric problems in their medical history. Mean Montgomery and 
Åsberg Depression Rating Scale (MADRS (range 0-60)) score was low, 3.1 (SD=4.9) 
(previously published (9)), and does not indicate depression. 
A second tick-bite followed by an erythema migrans occurred in five patients in the period
between LNB and 30 months follow-up, and all five received 14 days of per oral antibiotics. 
One patient had re-infection with LNB at follow up visit and was treated with intravenous 
ceftriaxone for 14 days.
Demographic and clinical factors
We found that pre-treatment symptom duration >6 weeks (B=-10.2, 95% CI -18.8- -6.7,
P=0.002) and non-complete recovery at 12 months (B=-5.6, 95% CI -10.8- -0.5, P=0.033) 
were associated with a worse PCS score. The R2 of 0.59 indicates that this final model 
explains 59% of the outcome variation. Non-complete recovery at 4 months (B=-8.9, 95% CI 
-15.5- -2.2, P=0.01) was associated with a worse MCS score. The R2 of 0.37 indicates that this 
final model explains 37% of the outcome variation. Pre-treatment symptom duration >6
weeks (B=1.3, 95% CI 0.15-2.4, P=0.028), a higher clinical score pre-treatment (B=0.1, 95% 
CI 0.002-0.2, P=0.019) and non-complete recovery at 12 months (B=1.7, 95% CI 0.7-2.6,
P=0.001) were associated with a worse FSS score. The R2 of 0.70 indicates that this final 
model explains 70% of the outcome variation.
CSF findings
Due to missing data we analyzed the CSF variables separately.  None of them reached a 
significance level of P= 0.05 or less in the univariate analyses or in the regression model.
Three patients (10%) had pleocytosis at 30 months follow-up (5, 6 and 66 white blood cell pr. 
mm3 (cell count below 5 /mm3 is regarded as normal)). The person with 66 cells had a tick-
bite a few weeks before follow-up, and developed new symptoms (neck pain, joint pain, 
asthenia, balance problems).We regarded this as a reinfection with Borrelia, and the patient 
recovered after a second course of antibiotics.
Eight patients (28%) had slightly elevated CSF protein level at 30 months, 17 (61%) had 
intrathecal anti-Borrelia antibody production, and 12 (43%) had presence of CSF oligoclonal 
bands. The CSF CXCL-13 was elevated in 23/32 (72%) of the patients pre-treatment, and in 
0/10 patients at 30 months (five of them reported remaining complaints).
DISCUSSION
We have previously found reduced HRQoL and more fatigue in Norwegian patients treated 
for LNB 30 months earlier as compared to matched controls (9). In the present study we 
wanted to identify risk factors for a non-favourable long term outcome with respect to 
HRQoL and fatigue. We found that pre-treatment symptom duration > 6 weeks and non-
complete recovery at 4 or 12 months post-treatment were associated with reduced HRQoL,
and that pre-treatment symptom duration more than 6 weeks, more complaints before 
treatment, and non-complete recovery 12 months after treatment were associated with a
higher burden of fatigue 30 months after treatment. Demographic factors like age, gender and 
educational level and clinical factors like diagnostic accuracy, treatment option, involvement
of the central nervous system, and coexisting diseases were not associated with HRQoL or 
fatigue burden in our cohort, neither were any of the assessed CSF findings pre-treatment or 
during follow-up like cell count, protein level, anti-Borrelia antibodies, oligoclonal bands or
CXCL-13 levels.
The association between reduced HRQoL and non-complete recovery is not unexpected from 
a clinical point of view, as non-complete recovery in this present study was defined as a score 
of >1  on a composite clinical score based on subjective complains and objective findings.
The association between a non-favorable long term HRQoL, prolonged time before antibiotic 
treatment and a higher burden of pre-treatment symptoms allow us to speculate if a more 
serious disease and longer duration of the disease before treatment can cause more permanent
neural damage, like in other CNS infections (25,26). Poorer long-term outcome in patients 
with pre-treatment signs of CNS involvement and/or high degree of CSF inflammation might 
have underscored such a theory, but we did not find such an association in our cohort, maybe 
due to a small sample size. Suggested theories of underlying pathological mechanisms for a 
poor HRQoL and fatigue after LNB are autoimmunity (27) and ongoing persistent infection
(28). We could not find laboratory support for any of these theories. None of our patients had
elevated cell count at follow-up, except for one patient with a Borrelia re-infection. Some had 
slightly elevated CSF protein, presence of CSF oligoclonal bands and persistent intrathecal 
anti-Borrelia antibody production at follow-up, but these findings were not associated with a 
non-favorable outcome, neither were any CSF findings pre-treatment. Furthermore, 
normalized CSF CXCL-13 level at 30 months post-treatment argues against an ongoing 
Borrelia infection, at least in the 10 patient who had their CSF analyzed for CXCL-13. 
Overall, the CSF findings at follow-up in this study should be interpreted with caution due to 
many missing data, and further research is recommended to elucidate laboratory signs of 
autoimmunity in patients with persistent long-term complaints after treated LNB. Another
debated theory of remaining complaints is that some patients might be more vulnerable
because of previous or current psychiatric conditions (29). We have shown in a previous study 
that patients in this cohort have the same amount of psychiatric comorbidity as a control 
group, and the MADRS scores were low (9).
We assessed the association between long-term HRQoL, fatigue and selected demographic, 
clinical and laboratory factors, but there may of course be other individual genetic and 
immunological factors which influence prognosis in different ways. Our statistical models 
explain between 40 to 70 % of the variation in the long-term outcome and there are probably 
several unknown factors involved. In addition to patient related factors, it is demonstrated in 
experimental models that different Borrelia burgdorferi species cause different clinical 
pictures, and it is possible that this can affect the long term outcome (30). It is also discussed 
if Anaplasma co-infection might worsen the outcome after Borrelia infection (31). We found 
no clinical or laboratory support of Anaplasma infection in our patient cohort.
Some previous studies have found delayed treatment to be predictive of a worse outcome 
(2,8,21). A US study including Quality of Life assessments found reduced HRQoL after 
Lyme disease as we did (5), others have not (20). A previous publication on this south 
Norwegian cohort showed that in addition to delayed treatment, female gender and high pre-
treatment CSF cell count were associated with non-complete clinical recovery one year after 
treatment (3). We did not find gender or pre-treatment CSF cell count to be predictive of the 
outcome at 30 months regarding HRQoL or fatigue. Whether the patients were treated with 
oral doxycycline or intravenous ceftriaxone, or had a definite or possible LNB did also not 
influence on the long-term HRQoL or fatigue in this cohort. This is in coherence with the 
treatment study showing similar efficacy of these two treatments (22).
The strengths of our study are the prospective design, a well defined patient group, and use of 
validated and reliable questionnaires. The linear regression model allows us to do
simultaneous assessment of multiple potential risk factors and to statistically explore their 
internal dependency of each other, and thus the analyses are more reliable than if only simple
comparisons are made.
Weaknesses of our study are the many missing data regarding CSF analyses and the lack of a 
prospectively followed control group, but we have previously shown that there is a significant 
difference between patients with LNB and controls regarding HRQoL and fatigue 30 months 
after treatment in this cohort (9). We asked about current medication at the time of the follow-
up, but there is a possibility that we might have missed some information of interventions 
initiated by other doctors like pain killers or non-inflammatory medications.
There are still many unknown factors regarding potential risk factors of a non-favorable long-
term outcome with respect to HRQoL and fatigue level after LNB, and our results are not 
applicable as prognostic hallmarks at an individual level. It seems reasonable though to avoid 
delay of antibiotic treatment, and to be aware of the possibility of fatigue after 30 months in 
those who have a more severe disease pre-treatment and do not recover completely after 12 
months.
Conclusion
Pre-treatment symptom duration of LNB more than 6 weeks and non-complete recovery at 12
months seem to predict a reduced HRQoL 30 months after treatment. More clinical findings 
and symptoms before and non-complete recovery 12 months after treatment seem to predict a 
higher fatigue burden 30 months after treatment. No CSF findings pre-treatment were 
associated to reduced HRQoL or more fatigue, neither were CSF findings at follow-up, but 
the latter should be interpreted with caution due to missing data.
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